Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
Most patients with recurrent ovarian cancer (ROC) undergo a series of remissions and recurrences, therefore the additive or cumulative toxicity of chemotherapy must be factored into their treatment plan. There are challenges in defining tailored therapeutic approaches, including optimal timing and d...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2014-12-01
|
| Series: | EJC Supplements |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1359634915700054 |